Eton Pharmaceuticals Inc. (ETON) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Eton Pharmaceuticals Inc. (NASDAQ: ETON) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $50.81 (-2.63% 1D, market cap $1.49B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, ETON ranks #191 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ETON carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of 53.5%, and ROIC of -0.9%. By comparison, OCUL (Ocular Therapeutix Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $1.53B) and INVA (Innoviva Inc.) posts a C grade (65/100 RQD, P/E N/A, ROIC 14.7%, cap $1.53B). Among the 5-stock peer group, ETON leads on earnings multiple (N/A) while INVA leads on capital efficiency (14.7% ROIC).
Per ETON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001710340), Eton Pharmaceuticals Inc. generated $80.0M in revenue (+104.9% YoY), -$4.6M in net income, and $10.2M in free cash flow against $92.1M in total assets and $21.8M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 13.37 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL FY 2025 (10-K): 12.7% FCF Margin ($10.2M FCF) & 53.5% Gross Margin
Dilution Drag (+1.64% YoY Shares) & executive Form 4 sales trim 14 pts from alignment
Even with a 57/100 (D+) score, ETON faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Dilution & Margin Drag: Dilution Drag (+1.64% YoY Shares) — any gross margin slip below 51.0% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($55.56) or 200D SMA ($36.08) invalidates the momentum regime and cuts Target Base ($50.58) toward Bear Floor ($39.45).
Eton Pharmaceuticals Inc. (ETON) dropped -2.63% to $50.81, trading at 70% of its 52-week range ($14.27 – $66.37). Stretched risk/reward at current multiples (-1% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Eton Pharmaceuticals Inc. (ETON) market action, institutional positioning, and fundamental catalysts.
ChartMill report covering Eton Pharmaceuticals Inc. (ETON) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Eton Pharmaceuticals Inc. (ETON) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Eton Pharmaceuticals Inc. (ETON) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Eton Pharmaceuticals Inc. (ETON) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Eton Pharmaceuticals Inc. (ETON) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Eton Pharmaceuticals Inc. (ETON) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Eton Pharmaceuticals Inc. (ETON) market action, institutional positioning, and fundamental catalysts.
ET-900 targets a potential new indication for mecasermin, the active ingredient in Eton’s INCRELEX®Eton has licensed patent rights from Baylor College of Medicine covering the use of insulin-like growth factor1 (IGF-1) f
ET-900 targets a potential new indication for mecasermin, the active ingredient in Eton’s INCRELEX®Eton has licensed patent rights from Baylor College of Medicine covering the use of insulin-like growth factor1 (IGF-1)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +104.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ETON today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ETON. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Eton Pharmaceuticals Inc. (ETON) ranks #191 by composite RQD confidence (57/100, grade D+) and #302 by equity capitalization ($1.49B). Within this direct 5-issuer industry benchmark cohort, ETON leads on earnings valuation at N/A trailing P/E, while INVA leads on capital efficiency and profitability with 14.7% ROIC and 74.8% gross margin. INVA currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with ETON at 57/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ETON
ACTIVE
Eton Pharmaceuticals Inc. | D+ | 57/100 | — | 53.5% | -0.9% | -2.63% | $1.49B | Benchmark Subject |
| OCUL Ocular Therapeutix Inc. | E | 24/100 | — | 87.3% | -35.0% | -3.44% | $1.53B | /ocul-vs-eton → |
| INVA Innoviva Inc. | C | 65/100 | — | 74.8% | 14.7% | -0.94% | $1.53B | /inva-vs-eton → |
| PCRX Pacira BioSciences Inc. | C | 65/100 | — | 79.4% | 1.7% | +0.03% | $1.45B | /pcrx-vs-eton → |
| TYRA Tyra Biosciences Inc. | E | 30/100 | — | — | -35.0% | +1.23% | $1.45B | /tyra-vs-eton → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Eton Pharmaceuticals Inc. (ETON) reported GAAP revenue of $80.0M (+104.9% vs. FY2024 revenue of $39.0M , and +152.7% cumulative change since FY2023) , GAAP net income of -$4.6M, operating cash flow of $10.5M, and free cash flow of $10.2M (+980.7% YoY). On the balance sheet, ETON closed FY2025 with $92.1M in total assets against $21.8M in total debt (Altman Z-Score: 13.37, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $80.0M | -$4.6M | $10.5M | $10.2M | $92.1M | $21.8M |
| FY2024 (FY) | 2024-12-31 | $39.0M | -$3.8M | $969.0K | $943.0K | $76.1M | $29.8M |
| FY2023 (FY) | 2023-12-31 | $31.6M | -$936.0K | $6.8M | $6.8M | — | — |
As of 2026-11-03, Eton Pharmaceuticals Inc. (NASDAQ: ETON) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $50.81 (-2.63% 1D, market cap $1.49B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, ETON ranks #191 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ETON carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of 53.5%, and ROIC of -0.9%. By comparison, OCUL (Ocular Therapeutix Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $1.53B) and INVA (Innoviva Inc.) posts a C grade (65/100 RQD, P/E N/A, ROIC 14.7%, cap $1.53B). Among the 5-stock peer group, ETON leads on earnings multiple (N/A) while INVA leads on capital efficiency (14.7% ROIC).
Per ETON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001710340), Eton Pharmaceuticals Inc. generated $80.0M in revenue (+104.9% YoY), -$4.6M in net income, and $10.2M in free cash flow against $92.1M in total assets and $21.8M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
ETON last traded at $50.81 (-2.63% on volume of 557,244 shares), positioning the stock -8.55% below its 50-day simple moving average ($55.56) and +40.83% above its 200-day simple moving average ($36.08). Across its 52-week range of $14.27 to $66.37, ETON sits at the 70.1% percentile with a 14-day RSI of 47.9 (NEUTRAL RANGE) and an implied next-earnings move of ±9.6% ($45.93 to $55.69).
Eton Pharmaceuticals Inc. (ETON) earns a live Roarable RQD composite score of 57/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $50.81 (-2.63% 1D, market capitalization $1.49B).
Eton Pharmaceuticals Inc. (ETON) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The company's market capitalization is $1.5B. Per the news wire, a headline references a new seizure drug license.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Eton Pharmaceuticals Inc. (ETON) reported $80.0M in annual revenue (up from $39.0M in FY2024, +104.9% YoY) and -$4.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($31.6M revenue, -$936.0K net income) through FY2025, ETON scaled operating cash flow to $10.5M and free cash flow to $10.2M, backed by $92.1M in total assets against $21.8M in total debt.
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), ETON carries a macro regime beta of 1.00 and gross margin of 53.5%.
Real-time company headlines, analyst actions, and sector developments for Eton Pharmaceuticals Inc. (ETON) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Eton Pharmaceuticals Inc. (ETON) market action, institutional positioning, and fundamental catalysts.
ChartMill report covering Eton Pharmaceuticals Inc. (ETON) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Eton Pharmaceuticals Inc. (ETON) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Eton Pharmaceuticals Inc. (ETON) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Eton Pharmaceuticals Inc. (ETON) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Eton Pharmaceuticals Inc. (ETON) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Eton Pharmaceuticals Inc. (ETON) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Eton Pharmaceuticals Inc. (ETON) market action, institutional positioning, and fundamental catalysts.
Long ETON at $52.18 targeting $62.62. Revenue grew from $31.6M in FY 2023 to $80.0M in FY 2025 while the balance sheet scores strongly on Altman Z of 13.37 and Piotroski F of 7/9.. Institutional whale score is 10/20 and the risk/reward vs. the $14.27 52-week low is skewed heavily in favor of bulls.
@FadeTheHype Shorting a 10/20 institutional whale-flow stock at $52.18 is dangerous when funds are rotating into Health Care.
Sitting on the sidelines or leaning short ETON above $52.18. ROIC is -0.9%, FCF yield is 0.66%, and the insider-conviction pillar scores only 6 of 20.. Until Fundamental Cash Engine (13/20) and FCF yield (0.66%) inflect higher, upside is capped near $66.37.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: